A Single Blood Test Finds More Early Cancers than Britain’s Screening Programs Combin

A single blood test finds more early cancers than Britain’s screening programs combin

Data presented at ASCO show Galleri detected more early-stage cancers than all existing UK screening programs combined and sharply increased diagnoses in a US real-world study; researchers stress it does not replace standard screening and survival benefits remain unproven

GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual Meeting

The Galleri Multi-Cancer Early Detection (MCED) Test Increased Cancer Detection 6.5 Fold When Added to Recommended Screenings for Breast, Colorectal, Cervical and Lung Cancer

Large Study Shows Multi-Cancer Early Detection Test Increases Cancer Detection

Results from the PATHFINDER 2 trial show the Galleri test identifies 6.5 times more cancers when used with standard screenings. GRAIL announced performance and safety results from the analysis of the full 35,878-participant cohort of its PATHFINDER 2 study. The data, presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, indicate that the Galleri multi-cancer early detection (MCED) test significantly increases cancer …